Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H19N3O5S.CH3Cl |
| Molecular Weight | 451.924 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCl.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C3=C(C)ON=C3C4=CC=CC=C4)C(O)=O
InChI
InChIKey=BAKWOCLQVPLVPO-SLINCCQESA-N
InChI=1S/C19H19N3O5S.CH3Cl/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22;1-2/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26);1H3/t13-,14+,17-;/m1./s1
DescriptionCurator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050640s017lbl.pdf
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050640s017lbl.pdf
Oxacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Oxacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Oxacillin results from the inhibition of cell wall synthesis and is mediated through Oxacillin binding to penicillin binding proteins (PBPs). Oxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Oxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Oxacillin interferes with an autolysin inhibitor. Oxacillin is used in the treatment of resistant staphylococci infections. Oxacillin sodium was marketed under the trade name Bactocill.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL5658 |
100.0 µM [IC50] | ||
Target ID: CHEMBL2362973 |
0.42 nM [IC50] | ||
Target ID: CHEMBL352 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Oxacillin Approved UseOxacillin is indicated in the treatment of infections caused by penicillinase producing
staphylococci which have demonstrated susceptibility to the drug. Launch Date1971 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
43 μg/mL |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
OXACILLIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
125.9 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6619039 |
30 mg/kg bw single, intravenous dose: 30 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
OXACILLIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.42 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6619039 |
30 mg/kg bw single, intravenous dose: 30 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
OXACILLIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
25 min |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
OXACILLIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6% |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
OXACILLIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
175 mg/kg/day 1 times / day multiple, intravenous Studied dose Dose: 175 mg/kg/day, 1 times / day Route: intravenous Route: multiple Dose: 175 mg/kg/day, 1 times / day Sources: |
unhealthy, mean age 4.96 years n = 8 Health Status: unhealthy Condition: sternal osteomyelitis Age Group: mean age 4.96 years Sex: M+F Population Size: 8 Sources: |
Other AEs: Elevated liver enzymes... |
175 mg/kg/day 1 times / day multiple, intravenous Studied dose Dose: 175 mg/kg/day, 1 times / day Route: intravenous Route: multiple Dose: 175 mg/kg/day, 1 times / day Sources: |
unhealthy, mean age 4.96 years n = 8 Health Status: unhealthy Condition: submandibular adenitis Age Group: mean age 4.96 years Sex: M+F Population Size: 8 Sources: |
Other AEs: Neutropenia... |
2 g 4 times / day multiple, intravenous Studied dose Dose: 2 g, 4 times / day Route: intravenous Route: multiple Dose: 2 g, 4 times / day Co-administed with:: dicloxacillin(500 mg orally; 4 per day) Sources: |
unhealthy, mean age 49.2 years n = 419 Health Status: unhealthy Condition: complicated skin and soft tissue infections Age Group: mean age 49.2 years Sex: M+F Population Size: 419 Sources: |
Other AEs: Nausea, Headache... Other AEs: Nausea (grade 1-2, 5.7%) Sources: Headache (grade 1-2, 3.8%) Vomiting (grade 1-2, 1.9%) Hypertension (grade 1-2, 0.2%) Diarrhea (grade 1-2, 2.9%) Pain localized (grade 1-2, 0.7%) Dyspepsia (grade 1-2, 1.7%) Insomnia (grade 1-2, 2.1%) Dizziness (grade 1-2, 0.7%) Abdominal pain (grade 1-2, 1.2%) Constipation (grade 1-2, 3.1%) Pruritus (grade 1-2, 2.1%) Fever (grade 1-2, 2.6%) |
12 g/day 1 times / day multiple, intravenous Studied dose Dose: 12 g/day, 1 times / day Route: intravenous Route: multiple Dose: 12 g/day, 1 times / day Sources: |
unhealthy, mean age 51 years n = 34 Health Status: unhealthy Condition: complicated bacteremia Age Group: mean age 51 years Sex: M+F Population Size: 34 Sources: |
Disc. AE: Transaminases increased, Leukopenia... Other AEs: Rash, Transaminases increased... AEs leading to discontinuation/dose reduction: Transaminases increased (11.8%) Other AEs:Leukopenia (3%) Blood sodium decreased (3%) Rash (3%) Rash (3%) Sources: Transaminases increased (18%) Creatinine serum increased (3%) Leukopenia (3%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Elevated liver enzymes | 12.5% | 175 mg/kg/day 1 times / day multiple, intravenous Studied dose Dose: 175 mg/kg/day, 1 times / day Route: intravenous Route: multiple Dose: 175 mg/kg/day, 1 times / day Sources: |
unhealthy, mean age 4.96 years n = 8 Health Status: unhealthy Condition: sternal osteomyelitis Age Group: mean age 4.96 years Sex: M+F Population Size: 8 Sources: |
| Neutropenia | 12.5% | 175 mg/kg/day 1 times / day multiple, intravenous Studied dose Dose: 175 mg/kg/day, 1 times / day Route: intravenous Route: multiple Dose: 175 mg/kg/day, 1 times / day Sources: |
unhealthy, mean age 4.96 years n = 8 Health Status: unhealthy Condition: submandibular adenitis Age Group: mean age 4.96 years Sex: M+F Population Size: 8 Sources: |
| Hypertension | grade 1-2, 0.2% | 2 g 4 times / day multiple, intravenous Studied dose Dose: 2 g, 4 times / day Route: intravenous Route: multiple Dose: 2 g, 4 times / day Co-administed with:: dicloxacillin(500 mg orally; 4 per day) Sources: |
unhealthy, mean age 49.2 years n = 419 Health Status: unhealthy Condition: complicated skin and soft tissue infections Age Group: mean age 49.2 years Sex: M+F Population Size: 419 Sources: |
| Dizziness | grade 1-2, 0.7% | 2 g 4 times / day multiple, intravenous Studied dose Dose: 2 g, 4 times / day Route: intravenous Route: multiple Dose: 2 g, 4 times / day Co-administed with:: dicloxacillin(500 mg orally; 4 per day) Sources: |
unhealthy, mean age 49.2 years n = 419 Health Status: unhealthy Condition: complicated skin and soft tissue infections Age Group: mean age 49.2 years Sex: M+F Population Size: 419 Sources: |
| Pain localized | grade 1-2, 0.7% | 2 g 4 times / day multiple, intravenous Studied dose Dose: 2 g, 4 times / day Route: intravenous Route: multiple Dose: 2 g, 4 times / day Co-administed with:: dicloxacillin(500 mg orally; 4 per day) Sources: |
unhealthy, mean age 49.2 years n = 419 Health Status: unhealthy Condition: complicated skin and soft tissue infections Age Group: mean age 49.2 years Sex: M+F Population Size: 419 Sources: |
| Abdominal pain | grade 1-2, 1.2% | 2 g 4 times / day multiple, intravenous Studied dose Dose: 2 g, 4 times / day Route: intravenous Route: multiple Dose: 2 g, 4 times / day Co-administed with:: dicloxacillin(500 mg orally; 4 per day) Sources: |
unhealthy, mean age 49.2 years n = 419 Health Status: unhealthy Condition: complicated skin and soft tissue infections Age Group: mean age 49.2 years Sex: M+F Population Size: 419 Sources: |
| Dyspepsia | grade 1-2, 1.7% | 2 g 4 times / day multiple, intravenous Studied dose Dose: 2 g, 4 times / day Route: intravenous Route: multiple Dose: 2 g, 4 times / day Co-administed with:: dicloxacillin(500 mg orally; 4 per day) Sources: |
unhealthy, mean age 49.2 years n = 419 Health Status: unhealthy Condition: complicated skin and soft tissue infections Age Group: mean age 49.2 years Sex: M+F Population Size: 419 Sources: |
| Vomiting | grade 1-2, 1.9% | 2 g 4 times / day multiple, intravenous Studied dose Dose: 2 g, 4 times / day Route: intravenous Route: multiple Dose: 2 g, 4 times / day Co-administed with:: dicloxacillin(500 mg orally; 4 per day) Sources: |
unhealthy, mean age 49.2 years n = 419 Health Status: unhealthy Condition: complicated skin and soft tissue infections Age Group: mean age 49.2 years Sex: M+F Population Size: 419 Sources: |
| Insomnia | grade 1-2, 2.1% | 2 g 4 times / day multiple, intravenous Studied dose Dose: 2 g, 4 times / day Route: intravenous Route: multiple Dose: 2 g, 4 times / day Co-administed with:: dicloxacillin(500 mg orally; 4 per day) Sources: |
unhealthy, mean age 49.2 years n = 419 Health Status: unhealthy Condition: complicated skin and soft tissue infections Age Group: mean age 49.2 years Sex: M+F Population Size: 419 Sources: |
| Pruritus | grade 1-2, 2.1% | 2 g 4 times / day multiple, intravenous Studied dose Dose: 2 g, 4 times / day Route: intravenous Route: multiple Dose: 2 g, 4 times / day Co-administed with:: dicloxacillin(500 mg orally; 4 per day) Sources: |
unhealthy, mean age 49.2 years n = 419 Health Status: unhealthy Condition: complicated skin and soft tissue infections Age Group: mean age 49.2 years Sex: M+F Population Size: 419 Sources: |
| Fever | grade 1-2, 2.6% | 2 g 4 times / day multiple, intravenous Studied dose Dose: 2 g, 4 times / day Route: intravenous Route: multiple Dose: 2 g, 4 times / day Co-administed with:: dicloxacillin(500 mg orally; 4 per day) Sources: |
unhealthy, mean age 49.2 years n = 419 Health Status: unhealthy Condition: complicated skin and soft tissue infections Age Group: mean age 49.2 years Sex: M+F Population Size: 419 Sources: |
| Diarrhea | grade 1-2, 2.9% | 2 g 4 times / day multiple, intravenous Studied dose Dose: 2 g, 4 times / day Route: intravenous Route: multiple Dose: 2 g, 4 times / day Co-administed with:: dicloxacillin(500 mg orally; 4 per day) Sources: |
unhealthy, mean age 49.2 years n = 419 Health Status: unhealthy Condition: complicated skin and soft tissue infections Age Group: mean age 49.2 years Sex: M+F Population Size: 419 Sources: |
| Constipation | grade 1-2, 3.1% | 2 g 4 times / day multiple, intravenous Studied dose Dose: 2 g, 4 times / day Route: intravenous Route: multiple Dose: 2 g, 4 times / day Co-administed with:: dicloxacillin(500 mg orally; 4 per day) Sources: |
unhealthy, mean age 49.2 years n = 419 Health Status: unhealthy Condition: complicated skin and soft tissue infections Age Group: mean age 49.2 years Sex: M+F Population Size: 419 Sources: |
| Headache | grade 1-2, 3.8% | 2 g 4 times / day multiple, intravenous Studied dose Dose: 2 g, 4 times / day Route: intravenous Route: multiple Dose: 2 g, 4 times / day Co-administed with:: dicloxacillin(500 mg orally; 4 per day) Sources: |
unhealthy, mean age 49.2 years n = 419 Health Status: unhealthy Condition: complicated skin and soft tissue infections Age Group: mean age 49.2 years Sex: M+F Population Size: 419 Sources: |
| Nausea | grade 1-2, 5.7% | 2 g 4 times / day multiple, intravenous Studied dose Dose: 2 g, 4 times / day Route: intravenous Route: multiple Dose: 2 g, 4 times / day Co-administed with:: dicloxacillin(500 mg orally; 4 per day) Sources: |
unhealthy, mean age 49.2 years n = 419 Health Status: unhealthy Condition: complicated skin and soft tissue infections Age Group: mean age 49.2 years Sex: M+F Population Size: 419 Sources: |
| Transaminases increased | 11.8% Disc. AE |
12 g/day 1 times / day multiple, intravenous Studied dose Dose: 12 g/day, 1 times / day Route: intravenous Route: multiple Dose: 12 g/day, 1 times / day Sources: |
unhealthy, mean age 51 years n = 34 Health Status: unhealthy Condition: complicated bacteremia Age Group: mean age 51 years Sex: M+F Population Size: 34 Sources: |
| Transaminases increased | 18% | 12 g/day 1 times / day multiple, intravenous Studied dose Dose: 12 g/day, 1 times / day Route: intravenous Route: multiple Dose: 12 g/day, 1 times / day Sources: |
unhealthy, mean age 51 years n = 34 Health Status: unhealthy Condition: complicated bacteremia Age Group: mean age 51 years Sex: M+F Population Size: 34 Sources: |
| Creatinine serum increased | 3% | 12 g/day 1 times / day multiple, intravenous Studied dose Dose: 12 g/day, 1 times / day Route: intravenous Route: multiple Dose: 12 g/day, 1 times / day Sources: |
unhealthy, mean age 51 years n = 34 Health Status: unhealthy Condition: complicated bacteremia Age Group: mean age 51 years Sex: M+F Population Size: 34 Sources: |
| Leukopenia | 3% | 12 g/day 1 times / day multiple, intravenous Studied dose Dose: 12 g/day, 1 times / day Route: intravenous Route: multiple Dose: 12 g/day, 1 times / day Sources: |
unhealthy, mean age 51 years n = 34 Health Status: unhealthy Condition: complicated bacteremia Age Group: mean age 51 years Sex: M+F Population Size: 34 Sources: |
| Rash | 3% | 12 g/day 1 times / day multiple, intravenous Studied dose Dose: 12 g/day, 1 times / day Route: intravenous Route: multiple Dose: 12 g/day, 1 times / day Sources: |
unhealthy, mean age 51 years n = 34 Health Status: unhealthy Condition: complicated bacteremia Age Group: mean age 51 years Sex: M+F Population Size: 34 Sources: |
| Blood sodium decreased | 3% Disc. AE |
12 g/day 1 times / day multiple, intravenous Studied dose Dose: 12 g/day, 1 times / day Route: intravenous Route: multiple Dose: 12 g/day, 1 times / day Sources: |
unhealthy, mean age 51 years n = 34 Health Status: unhealthy Condition: complicated bacteremia Age Group: mean age 51 years Sex: M+F Population Size: 34 Sources: |
| Leukopenia | 3% Disc. AE |
12 g/day 1 times / day multiple, intravenous Studied dose Dose: 12 g/day, 1 times / day Route: intravenous Route: multiple Dose: 12 g/day, 1 times / day Sources: |
unhealthy, mean age 51 years n = 34 Health Status: unhealthy Condition: complicated bacteremia Age Group: mean age 51 years Sex: M+F Population Size: 34 Sources: |
| Rash | 3% Disc. AE |
12 g/day 1 times / day multiple, intravenous Studied dose Dose: 12 g/day, 1 times / day Route: intravenous Route: multiple Dose: 12 g/day, 1 times / day Sources: |
unhealthy, mean age 51 years n = 34 Health Status: unhealthy Condition: complicated bacteremia Age Group: mean age 51 years Sex: M+F Population Size: 34 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Incidence of Chlamydia trachomatis and other potential pathogens in neonatal conjunctivitis. | 2001 |
|
| Antibacterials for the prophylaxis and treatment of bacterial endocarditis in children. | 2001 |
|
| [Evaluation of MRSA identification with latex agglutination kit for the detection of penicillin-binding protein 2]. | 2001 |
|
| [Monitoring of uropathogens and their susceptibility to antibiotics]. | 2001 |
|
| Rapid detection of the methicillin-resistance gene, mecA, in coagulase-negative Staphylococci. | 2001 |
|
| Optimisation of the prevention and treatment of bacterial endocarditis. | 2001 |
|
| Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program. | 2001 Aug |
|
| [Coagulase negative staphylococci isolated on blood cultures]. | 2001 Aug |
|
| Multi-resistance to antimicrobial agents for the ten most frequently isolated bacterial pathogens. | 2001 Aug |
|
| Therapeutic options for Gram-positive infections. | 2001 Dec |
|
| Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model. | 2001 Dec |
|
| Evaluation of a reverse hybridization blot test for detection of oxacillin-resistant Staphylococcus aureus. | 2001 Dec |
|
| Natural antibiotic susceptibility of strains of the Enterobacter cloacae complex. | 2001 Dec |
|
| Susceptibility of Arcobacter butzleri isolates to 23 antimicrobial agents. | 2001 Dec |
|
| Crystallization and preliminary X-ray study of OXA-1, a class D beta-lactamase. | 2001 Dec |
|
| Antibiotic resistance in coagulase-negative staphylococci isolated from Cope's gray treefrogs (Hyla chrysoscelis). | 2001 Dec 18 |
|
| A microdilution plating method for population analysis of antibiotic-resistant staphylococci. | 2001 Fall |
|
| Susceptibility of bacterial isolates to cefepime in comparison to other broad spectrum antimicrobial agents at a tertiary care center in Lebanon. | 2001 Jan-Feb |
|
| Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. | 2001 Jul |
|
| Generation of class-selective monoclonal antibodies against the penicillin group. | 2001 Jul |
|
| In vitro antimicrobial activity of the aminoglycoside arbekacin tested against oxacillin-resistant Staphylococcus aureus isolated in Brazilian hospitals. | 2001 Jun |
|
| Changing antibiotic sensitivity patterns at a university hospital, 1992 through 1999. | 2001 Jun |
|
| Natural antibiotic susceptibility of recently established coryneform bacteria. | 2001 May |
|
| Changing pattern of antibiotic resistance in methicillin-resistant Staphylococcus aureus from German hospitals. | 2001 Nov |
|
| Evaluation of the MRSA-Screen Test in detecting oxacillin resistance in community and hospital isolates of Staphylococcus aureus. | 2001 Nov |
|
| Direct detection of mecA, nuc and 16S rRNA genes in BacT/Alert blood culture bottles. | 2001 Nov |
|
| Molecular characterization of a chromosomal locus in Staphylococcus aureus that contributes to oxidative defence and is highly induced by the cell-wall-active antibiotic oxacillin. | 2001 Nov |
|
| Antimicrobial susceptibility of staphylococci isolated from the faeces of wild turkeys (Meleagris gallopavo). | 2001 Nov |
|
| Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. | 2001 Nov |
|
| Vancomycin-intermediate Staphylococcus aureus in a home health-care patient. | 2001 Nov-Dec |
|
| [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections]. | 2001 Sep |
|
| Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998. | 2001 Sep |
|
| The DUEL study: a multi-center in vitro evaluation of linezolid compared with other antibiotics in the Netherlands. | 2001 Sep |
|
| [Evaluation of the E-test and the ATB-PNEUMo battery for determining the beta-lactam MIC for Streptococcus pneumoniae in daily practice]. | 2001 Sep |
|
| Staphylococcus lugdunensis: an emerging cause of ventriculoperitoneal shunt infections. | 2001 Sep |
|
| Determination of benzylpenicillin, oxacillin, cloxacillin, and dicloxacillin in cows' milk by ion-pair high-performance liquid chromatography after precolumn derivatization. | 2001 Sep |
|
| Staphylococcus aureus in lower respiratory infections: clinical relevance of antimicrobial resistance. | 2001 Sep |
|
| Epigallocatechin gallate synergy with ampicillin/sulbactam against 28 clinical isolates of methicillin-resistant Staphylococcus aureus. | 2001 Sep |
|
| Cloning and sequencing of the gene, fmtC, which affects oxacillin resistance in methicillin-resistant Staphylococcus aureus. | 2001 Sep 11 |
|
| Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. | 2001 Winter |
|
| Comparative antimicrobial spectrum and activity of BMS284756 (T-3811; a desfluoroquinolone) tested against an international collection of staphylococci and enterococci, including in vitro test development and intermethod comparisons. | 2002 Feb |
|
| A comparison of PCR detection of mecA with two standard methods of oxacillin disk susceptibility testing for coagulase-negative staphylococci. | 2002 Jan |
|
| Prediction of mecA-positive coagulase-negative staphylococci: assessment of different phenotypic methods, breakpoints, culture media and culture conditions. | 2002 Jan |
|
| An outbreak of community-acquired foodborne illness caused by methicillin-resistant Staphylococcus aureus. | 2002 Jan |
|
| Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. | 2002 Jan |
|
| Surveillance for antimicrobial resistance in Croatia. | 2002 Jan |
|
| Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. | 2002 Jan 1 |
|
| Simultaneous detection of the mecA and ileS-2 genes in coagulase-negative staphylococci isolated from Brazilian hospitals by multiplex PCR. | 2002 Mar |
|
| A European study on the relationship between antimicrobial use and antimicrobial resistance. | 2002 Mar |
|
| In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates. | 2002 Mar |
Sample Use Guides
Oxacillin Injection, USP supplied as a premixed frozen solution is to be administered as a
continuous or intermittent intravenous infusion. The usual dose recommendation is as
follows:
Adults
250-500 mg I.V. every 4-6 hours (mild to moderate infections)
1 gram I.V. every 4-6 hours (severe infections)
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
156613694
Created by
admin on Sat Dec 16 11:17:53 GMT 2023 , Edited by admin on Sat Dec 16 11:17:53 GMT 2023
|
PRIMARY | |||
|
EKZ8N76PTN
Created by
admin on Sat Dec 16 11:17:53 GMT 2023 , Edited by admin on Sat Dec 16 11:17:53 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
